 "Morepen to go big on therapies for preventive cardiology & diabetology")
Pharmaceutical company Morepen Laboratories plans to expand its services in the diagnostics and therapy segment in the coming years. Dr Morepen Now, a wholly owned subsidiary of Morepen Laboratories, which has already begun its foray in the healthcare segment in Delhi, wants to take the service into other parts of the country, making it a pan-India offering.
Dr Morepen Now’s CEO Varun Suri told Business Standard that the company would open around 200 clinics across the country, some as franchises and others owned by Morepen Laboratories. The company is yet to finalise a model for letting people open franchises.
Dr Morepen Now is also entering into a strategic partnership with Singapore-based Renew Group to expand its centres a few years from now.
Suri said the investment would be around Rs 1.5 crore per clinic. To begin with, metro and Tier-I cities will be a priority, after which Tier-II cities will be targeted.
The first clinic in Delhi’s Hauz Khas will be a prototype for others. “Dr Morepen Now is the pioneer in bringing the nitric-oxide test to India,” said Suri. Nitric-oxide test is used to assess whether one is prone to heart-diseases or not.
When asked how different Dr Morepen Now is from other labs and healthcare outlets, Suri said theirs is a no-surgery approach, which is technically known as ‘external counter pulsation’. Dr Morepen Now’s belief is that a person’s well-being can be determined by the shape in which his heart is. That’s why all tests here are done beginning with the heart, says Suri.
Dr Morepen Now plans to focus only on therapy keeping its pathological segment at a bare minimum. At present, its pathology segment is around five per cent of the whole outlet.
